SI
ALXO icon

Sofinnova Investments’s ALX Oncology ALXO Stock Holding History

Sofinnova Investments’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-107,220
Closed -$7.92M – 71
2021
Q3 		$7.92M Buy
+107,220
New +$7.15M 0.47% 44

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Sofinnova Investments's ALXO Position: Q4 2021 in Review

Sofinnova Investments sold out of ALX Oncology (ALXO) in Q4 2021, closing a stake of 107,220 shares — an estimated $7.92M sold.

Sofinnova Investments first reported a position in ALXO in Q3 2021 and held it in 1 quarter. The position peaked at $7.92M in Q3 2021. 108 funds tracked by Wall St. Rank hold ALXO as of Q4 2021.

  • Sofinnova Investments reported no remaining ALX Oncology position as of Q4 2021 after selling out during the quarter.
  • Sofinnova Investments sold 107,220 ALX Oncology shares in Q4 2021, an estimated $7.92M.
  • Sofinnova Investments first reported a position in ALX Oncology in Q3 2021 and held it in 1 quarter.
  • Sofinnova Investments's ALX Oncology position peaked at $7.92M in Q3 2021.
  • 108 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2021.

Based on Sofinnova Investments's 13F filing for Q4 2021, filed 14 Feb 2022.